Analystreport

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com